Novo Nordisk A/S (NVO)
| Market Cap | 339.35B |
| Revenue (ttm) | 40.31B |
| Net Income (ttm) | 14.02B |
| Shares Out | 4.44B |
| EPS (ttm) | 3.14 |
| PE Ratio | 24.16 |
| Forward PE | 18.96 |
| Dividend | $1.30 (1.71%) |
| Ex-Dividend Date | Mar 31, 2025 |
| Volume | 7,523,679 |
| Open | 76.02 |
| Previous Close | 74.79 |
| Day's Range | 75.40 - 77.34 |
| 52-Week Range | 73.80 - 148.15 |
| Beta | 0.17 |
| Analysts | Strong Buy |
| Price Target | 141.67 (+86.68%) |
| Earnings Date | May 7, 2025 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for NVO stock is "Strong Buy." The 12-month stock price forecast is $141.67, which is an increase of 86.68% from the latest price.
News
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo Nordisk To Contact Him Directly To Discuss Their Options If you purchased or acq...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in Novo Nordisk A/S Lawsuit - NVO
NEW YORK , March 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class peri...
Novo Nordisk sell-off is completely overdone, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk stock nearing two-year lows.
Final Trade: AAPL, NVO, ADBE, FCX
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
How a Novo Nordisk Foundation-funded project sparked ultra-processed food fight
The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the world understands ultra-processed foods, after more than 90 independent food sc...
Healthy Returns: Wegovy is linked to an increased risk of hair loss, study suggests
Novo Nordisk's weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom received a warning letter from FDA.
Novo Nordisk's Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trial
On Monday, Novo Nordisk A/S NVO announced headline results from the REDEFINE 2 phase 3 trial in the global REDEFINE program.
Novo Nordisk: CagriSema Disappoints Again
Novo Nordisk: CagriSema Disappoints Again
Novo Nordisk shares fall on weight-loss drug trial
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
Novo Nordisk Stock Drops on New Obesity Drug Finding. Eli Lilly Stands to Gain.
The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.
NVO Weight Loss Drug Disappoints, RDFN Acquisition, Airline Price Targets Slashed
Market weakness continued this morning, including in international companies like Novo Nordisk (NVO). Its next-gen weight loss drug trial results weren't enough to draw investors in.
Novo Nordisk Shares Sink on Latest CagriSema Weight Loss Drug Study
Novo Nordisk's (NVO) U.S.-listed shares fell Monday morning following the release of data for a new phase 3 clinical trial of its in-development weight loss drug CagriSema.
Novo Nordisk shares slide 6% after weight loss drug trial disappoints
Novo Nordisk shares declined on Monday after the company reported that its next-generation weight-loss drug, CagriSema, helped obese or overweight adult patients with type 2 diabetes reduce their weig...
Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results
The pharmaceutical giant released fresh trial data showing the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight.
Novo Nordisk shares fall 5.5% after latest trial results for its next-generation weight loss drug
Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.
Novo Nordisk says trial with next-gen drug in diabetics shows 15.7% weight loss
Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 diabetes cut their weight by 15.7% after 68 weeks.
Buy Two Ideal March 'Safer' Dividend Dogs Of 34 Barron's 2025 Pro-Picks
Barron's New-Year (NY) Roundtable (RT) selections published in three issues 1/13-27/2025, listed 34 dividend picks as the best of 2025. Analysts predict top picks like AdvanSix, Applied Materials, and...
Final Trade: GOOGL, NVO, GDX, MP
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
NVO, LLY and AMGN Forecast – Pharma Stocks Look Mixed in Premarket
Three of the major pharma companies that I follow have shown a bit of a mixed move in the premarket hours, as the markets try to get a grip on the latest demand for GLP-1 and other medicines.
Novo Nordisk to explore how GLP-1 drugs can help patients with addiction
Novo Nordisk will explore how GLP-1 drugs potentially could help patients struggling with addiction, its head of development Martin Holst Lange told an online press conference on Thursday.
Novo Nordisk Drops Price of Weight-Loss Drug Wegovy for Some Patients Paying Out of Pocket
Novo Nordisk (NVO) is lowering the price of its popular weight-loss drug Wegovy for some patients paying out of pocket.
Novo Nordisk cuts Wegovy prices in half for cash-paying consumers
Novo Nordisk is cutting the price of its weight-loss drug, Wegovy, and selling it through a direct-to-patient online pharmacy to reach more people who aren't covered.
Novo Nordisk slashing price of Wegovy to $499 a month to uninsured following rival's move
The weight-loss drug can cost patients more than $1,000 a month if they do not have health insurance coverage.
Novo Nordisk's Cheaper Wegovy Offering Is Bad News for Hims & Hers
The announcement comes weeks after the FDA declared that Wegovy is no longer in shortage.
Novo Nordisk Boosts Wegovy Access With Lower Pricing and Home Delivery
On Wednesday, Novo Nordisk A/S NVO introduced NovoCare Pharmacy, a direct-to-patient delivery service to improve access to Wegovy (semaglutide) for cash-paying patients.